Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
718 (USA) · Dr. Nolan
consented 2013-07-07
Adverse events
Moderate AGITATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-07-18 (study day 12.0); relationship: POSSIBLE
Moderate INFLAMMATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-07-30 (study day 24.0); relationship: REMOTE
Severe SYNCOPE — outcome: RECOVERED/RESOLVED; onset 2013-07-16 (study day 10.0); relationship: POSSIBLE; serious criteria: hospitalization
Severe SYNCOPE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-07-30 (study day 24.0); relationship: POSSIBLE; serious criteria: hospitalization
Data queries
No data queries.